Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

53P - Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Jose Carlos Benitez

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

J.C. Benitez1, M. Boucher2, E. Dansin3, M. Kerjouan4, I. Bigay-Game5

Author affiliations

  • 1 Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif/FR
  • 2 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 3 Centre Oscar Lambret, Lille/FR
  • 4 Centre Hospitalier Universitaire de Rennes, Rennes/FR
  • 5 Centre Hospitalier Universitaire de Toulouse, Toulouse/FR
More

Abstract 53P

Background

TET are associated with autoimmune disorders (AID) in up to 30% of patients (pts). However, there have been wide variations in the reported prevalence of AID in TET pts in small single-center series. RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French network mandated to systematically discuss every case of TET. We aimed to describe risk factors of AID in a large French population.

Methods

RYTHMIC database, hosted by IFCT (Intergroupe Francophone de Cancérologie Thoracique), prospectively includes all consecutive pts with a diagnosis of TET discussed in French national or regional tumor boards. We analyzed epidemiologic, clinical and pathological characteristics of pts with TET’s related AID.

Results

From January 2012 to December 2019, 2909 pts were included in the registry. The Median Age at diagnosis was 63,5 (range 9 to 91). There were 590 (20.2%) events of AID in 552 pts, mainly females (53.4%). 21 pts (3.8%) had more than 1 AID. AID events are represented in the table. Diagnosis of AID was either done at tumor diagnosis (n=477, 81%), before diagnosis (n=75, 12.6%) or during follow up (FU) (n=38, 6.4%). 21/411 (5.1%) pts have subclinical myasthenia gravis (i.e. Ach-R positive antibodies without symptoms). In 8.8% (25/283) of pts, AID occurred at recurrence. Thymoma B2 has the highest prevalence of AID (n=187/541, 34.6%) and thymic carcinoma (TC) (n=11/248, 4.4%) the lowest. Overall, presenting AIDs was an independent good prognostic factor for relapse (HR=0,75, 95%CI[0,58-0,99]; p=0,04) but not for survival. There was some heterogeneity among AID since pts presenting Good’s syndrome and neuropathy had higher risk of relapse (HR=4.2, 95%CI[1.8-9.8]; p=0.001 and HR=5.9, 95%CI[1.06-20.17]; p=0.004 respectively). Among pts with AID, the risk of relapse was higher with B1 and B2 subtypes (OR=3, p=0.04 and OR=1.7, p=0.19; respectively). Surgery improved the AID outcome in pts with AB TET (OR=7.4, p=0.04). TC showed risk for AID during FU (OR=1.5, p=0.5). Table: 53P

AID (n=590)
N %
Myasthenia Gravis 411 69.6%
Red cell aplasia 17 2.8%
Good’s Symdrome 33 5.6%
Thyroiditis 20 3.4%
Lupus 26 4.4%
Arthritis 13 2.2%
Glomerulonephritis 8 1.3%
Neuropathy 11 2%
Sjögren syndrome 5 1%
Dermatomyositis 9 1.5%
Others# 37 6.2%

Table # Others: Hemolytic Anemia (n=4), Encephalitis (n=3), Vasculitis (n=2), colitis (n=2), Sclerodermia (n=1), thrombocytopenia (n=2), hepatitis (n=1), Behçet disease (n=1), chronic pruritus (n=1), vitiligo (n=2), myocarditis (n=1), Ankylosing spondylitis (n=2), Sarcoidosis (n=1), others (n=14).

Conclusions

The prevalence of AID in pts with TET was 20.2%. Diagnosis of AID can be subclinical and delayed compared to the diagnosis of TET, sometimes as a recurrence event including TC. Immunotherapy indication should be carefully assessed in pts with TET other than TC with a tight FU.

Legal entity responsible for the study

IFCT and RYTHMIC network.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.